US Bancorp DE bought a new position in Revvity, Inc. (NYSE:RVTY – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 65,483 shares of the company’s stock, valued at approximately $7,158,000. US Bancorp DE owned approximately 0.05% of Revvity at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. 2Xideas AG purchased a new position in Revvity in the 3rd quarter worth about $20,968,000. Citigroup Inc. purchased a new stake in Revvity in the third quarter worth approximately $5,548,000. Wesbanco Bank Inc. bought a new stake in Revvity in the 3rd quarter worth approximately $522,000. Headinvest LLC bought a new position in shares of Revvity during the 3rd quarter valued at $57,000. Finally, Vanguard Group Inc. purchased a new position in shares of Revvity in the 3rd quarter worth $1,579,487,000. 86.65% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts recently commented on RVTY shares. TD Cowen upped their price objective on Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. KeyCorp increased their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Stifel Nicolaus boosted their target price on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Raymond James increased their price target on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, Robert W. Baird boosted their price objective on shares of Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a research report on Tuesday, April 30th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.
Check Out Our Latest Analysis on RVTY
Revvity Price Performance
Shares of Revvity stock opened at $113.27 on Tuesday. The company has a market capitalization of $13.98 billion, a price-to-earnings ratio of 93.61, a PEG ratio of 2.94 and a beta of 1.09. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40. The stock’s 50-day simple moving average is $104.92 and its 200-day simple moving average is $103.14. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $131.96.
Revvity (NYSE:RVTY – Get Free Report) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The company had revenue of $649.90 million for the quarter, compared to analysts’ expectations of $646.83 million. During the same period in the previous year, the firm earned $1.01 EPS. The firm’s revenue was down 3.7% compared to the same quarter last year. As a group, analysts expect that Revvity, Inc. will post 4.66 earnings per share for the current fiscal year.
Revvity Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.25%. Revvity’s dividend payout ratio is 23.14%.
About Revvity
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
See Also
Receive News & Ratings for Revvity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revvity and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
